Shilpa Medicare Ltd 2021 AR2
The report highlights Shilpa Medicare Limited's performance for the fiscal year 2020-21, during which the company achieved a standalone total income growth of 6% to reach INR 86,422 Lakhs. Key developments included the expansion of the Tranexamic acid production block capacity from 5.5 MT to 15 MT and the launch of several new oncology and non-oncology products. Additionally, the company entered into a definitive agreement with Dr. Reddy's Laboratories for the production and supply of the Sputnik V vaccine. On the environmental front, the company saved 201,963 KWh of energy through modernization and reduced fresh water consumption by 40% using recycled treated wastewater.
Company: Shilpa Medicare Ltd
Sector: Manufacturing
Country: India
Year: 2021
Type: AR2
Pages: 238
Back to company
Shilpa Medicare Ltd
Annual Report
The report highlights Shilpa Medicare Limited's performance for the fiscal year 2020-21, during which the company achieved a standalone total income growth of 6% to reach INR 86,422 Lakhs. Key developments included the expansion of the Tranexamic acid production block capacity from 5.5 MT to 15 MT and the launch of several new oncology and non-oncology products. Additionally, the company entered into a definitive agreement with Dr. Reddy's Laboratories for the production and supply of the Sputnik V vaccine. On the environmental front, the company saved 201,963 KWh of energy through modernization and reduced fresh water consumption by 40% using recycled treated wastewater.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2021
Reporting Period
Apr 1, 2020 - Mar 31, 2021
Fiscal Year
2021
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Employees